Image quality and quantification accuracy dependence on patient body mass in 89Zr PET/CT imaging

[1] Verel I(2005)The promise of immuno-PET in radioimmunotherapy J Nucl Med 46 164S-171S

[2] Visser GW(2006)Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning Clin Cancer Res 12 1958-1960

[3] van Dongen GA(2008)Monoclonal antibodies as innovative therapeutics Curr Pharm Biotechnol 9 423-430

[4] Zalutsky MR(2011)PET tracers based on zirconium-89 Curr Radiopharm 4 131-139

[5] Reichert JM(2019)Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma Eur J Nucl Med Mol Imaging 46 1931-1939

[6] Zhang Y(2009)Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging J Nucl Med 50 974-981

[7] Hong H(2018)(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up Eur J Nucl Med Mol Imaging 45 2300-2306

[8] Cai W(2016)Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial Ann Oncol 27 619-624

[9] Verhoeff SR(2014)FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 Eur J Nucl Med Mol Imaging. 42 328-354

[10] van Es SC(2014)Multicenter harmonization of 89Zr PET/CT performance J Nucl Med 55 264-267

[1] Verel I(2005)The promise of immuno-PET in radioimmunotherapy J Nucl Med 46 164S-171S

[2] Visser GW(2006)Potential of immuno-positron emission tomography for tumor imaging and immunotherapy planning Clin Cancer Res 12 1958-1960

[3] van Dongen GA(2008)Monoclonal antibodies as innovative therapeutics Curr Pharm Biotechnol 9 423-430

[4] Zalutsky MR(2011)PET tracers based on zirconium-89 Curr Radiopharm 4 131-139

[5] Reichert JM(2019)Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma Eur J Nucl Med Mol Imaging 46 1931-1939

[6] Zhang Y(2009)Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging J Nucl Med 50 974-981

[7] Hong H(2018)(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up Eur J Nucl Med Mol Imaging 45 2300-2306

[8] Cai W(2016)Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial Ann Oncol 27 619-624

[9] Verhoeff SR(2014)FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 Eur J Nucl Med Mol Imaging. 42 328-354

[10] van Es SC(2014)Multicenter harmonization of 89Zr PET/CT performance J Nucl Med 55 264-267